For decades, treating glaucoma has meant playing defense—lowering the pressure inside the eye and hoping, essentially, that the damage stops there. It doesn't always. The retinal ganglion cells that connect eye to brain keep dying off, and with them goes vision that no amount of pressure management can restore.
Tavo Biotherapeutics, a small Laguna Beach outfit, believes it has something different. The company announced a $17 million Series A round on June 2, 2026, led by Pureos Bioventures, with Polaris Partners and existing investor Tau Capital joining in. The money will push TAV-001—a topical therapy designed to both lower intraocular pressure and protect the optic nerve from degeneration—into Phase 2 trials slated to begin in the second half of this year.
If it works, and that's still very much an if, it would represent a genuine departure from the current playbook.
"We could be looking at the first disease-modifying pharmaceutical therapy for glaucoma," the company says in its materials. Perhaps. The claim hinges on whether clinical endpoints can prove functional benefits beyond the pressure reductions that existing drugs already deliver.
New Faces, Familiar Pedigrees
The funding came with notable additions to Tavo's leadership roster. Federico Grossi, MD, PhD, signed on as Chief Medical Officer—he was most recently at Apellis, where he worked on SYFOVRE for geographic atrophy and EMPAVELI for a rare blood disorder. Daniel Bradbury, who ran Amylin Pharmaceuticals before its acquisition by Bristol-Myers Squibb, took the board chairman role.
Two investors also joined the board: Dominik Escher, PhD, a founding partner at Pureos with ophthalmology credentials stretching back to ESBATech's sale to Alcon, and Nil Gural, PhD, a principal at Polaris Partners.
It's the kind of biotech bench depth that signals ambition, though ambition and clinical success don't always travel together.
The Science—And the Gap It's Trying to Fill
TAV-001 is a topical treatment, which matters in a field where patient compliance can make or break outcomes. The company describes a dual mechanism: managing autonomic control of aqueous humor dynamics to reduce pressure while simultaneously guarding retinal ganglion cells against excitotoxicity and other neurodegenerative processes.
Glaucoma's toll is projected to climb steeply. A January 2026 meta-analysis estimated that open-angle glaucoma will affect 186.6 million people globally by 2060, more than double the roughly 80.5 million counted today. Yet neuroprotective therapies—drugs that directly shield the optic nerve—remain frustratingly scarce. Most are stuck in preclinical limbo or early trials.
The standard treatments on pharmacy shelves lower pressure. They don't protect neurons. That's the gap Tavo is chasing.
The company isn't alone in recognizing the opening. Bayer said in May it would acquire Perfuse Therapeutics for PER-001, an endothelin antagonist implant that showed encouraging signals in Phase 2 for visual field improvement and optic nerve blood flow. Spinogenix presented preclinical data at ARVO 2026 on a synaptic regenerative approach.
What distinguishes Tavo's bet is delivery: a topical drop rather than an implant, combining pressure control and neuroprotection in a single molecule. Whether that translates into clinical differentiation remains an open question.
What Comes Next
TAV-001 has reportedly cleared a Phase 1b study. The Series A capital will fund its Phase 2 trial launch in the second half of 2026 and support continued work on TAV-002, a preclinical bispecific antibody program aimed at wet and dry age-related macular degeneration and diabetic retinopathies. No trial start date has been disclosed for that second program—it's further down the pipeline.
Tavo surfaced among exhibitors at the American Glaucoma Society's annual meeting in May, a sign the company is cultivating relationships within the clinical ophthalmology community ahead of its pivotal trial.
For now, the science is unproven but the need is undeniable. Glaucoma doesn't wait, and neither does the clock on those 186 million projected patients. The company recently raised funds and added new team members with relevant history in ophthalmology and biotech to make its case. Whether TAV-001 can deliver on its dual promise will become clearer once those Phase 2 results start to come in—probably sometime in late 2027 or early 2028, if timelines hold.
That's when the real test begins.
